Seeking Alpha EN

Bolt Biotherapeutics GAAP EPS of -$3.84 beats by $1.57, revenue of $2.5M beats by $1.64M

Mar 12, 2026 &03431212202631; 20:43 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

→

Neutral impact

Sentiment score: +15/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Bolt Biotherapeutics reported a GAAP EPS of -$3.84, beating expectations by $1.57, with revenue of $2.5M exceeding estimates by $1.64M. Despite the earnings beat, the company remains unprofitable with significant losses, indicating early-stage development status.

AI CONFIDENCE

65% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

⇅

BOLT

BOLTStock

High volatility expected

Positive earnings surprise offset by continued substantial losses and minimal revenue base typical of early-stage biotech

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Monitor for clinical trial updates and cash runway announcements. The earnings beat is positive but should be contextualized within the company's pre-revenue/early-revenue stage; focus on pipeline progress rather than near-term profitability for investment decisions.

KEY SIGNALS

EPS beat by $1.57 vs expectationsRevenue beat by $1.64MNegative GAAP EPS of -$3.84 indicates ongoing lossesLow absolute revenue of $2.5M suggests pre-commercial stageEarnings surprise may attract short-term traders but fundamentals remain weak

SECTORS INVOLVED

BiotechnologyHealthcarePharmaceuticals

Analysis generated on Mar 16, 2026 at 16:15 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Bolt Biotherapeutics GAAP EPS of -$3.84 beats by $1.57, revenue of $2.5M beats by $1.64M

RELATED INTELLIGENCE